• Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

  • Oct 17 2024
  • Durée: 43 min
  • Podcast

Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • “Our liquid biopsy test alone, we estimate one in four cancer patients in the US are getting it,” Helmy Eltoukhy, cofounder and co-CEO of Guardant Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Eltoukhy joins BI analyst Jonathan Palmer to discuss the underpinnings of the liquid biopsy revolution and how Guardant has stuck to its technology road map since its founding in 2012, launching products in each of the three major market categories. The conversations also covers the company’s recent approval of its Shield colorectal screening test as well as many of the scientific and commercial challenges to standing up the business.

    See omnystudio.com/listener for privacy information.
    Voir plus Voir moins
Voir plus Voir moins
activate_Holiday_promo_in_buybox_DT_T2

Ce que les auditeurs disent de Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.